Analystreport

Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.

Allogene Therapeutics, Inc.  (ALLO) 
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report